Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 8,221 |
|
|||||
| News | - | ||||||
| Day High | 1.06 | Low High |
|||||
| Day Low | 1.02 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oragenics Inc | OGEN | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.01 | 18:19:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.05 | 1.02 | 1.06 | 1.035 | 1.01 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 145 | 8,221 | US$ 1.04 | US$ 8,576 | - | 1.00 - 7.74 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:44:19 | 1 | US$ 1.06 | USD |
Oragenics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 2.57M | - | 38k | -20.66M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oragenics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/19/2024 | 16:50 | Business Wire | Oragenics, Inc. Announces Notification of Noncompliance with.. |
| 4/01/2024 | 08:05 | Business Wire | Oragenics, Inc. Files 10K and Provides Company Update |
| 3/18/2024 | 06:00 | Business Wire | Oragenics Appoints James Kelly MD, Chief Medical Officer, to.. |
| 3/06/2024 | 15:24 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 3/05/2024 | 06:45 | Business Wire | Oragenics, Inc. Prepares Drug for Phase II Clinical Trials.. |
| 3/01/2024 | 15:04 | Business Wire | Oragenics Announces Closing of Public Offering |
| 2/29/2024 | 15:41 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/28/2024 | 08:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/27/2024 | 20:25 | Business Wire | Oragenics Announces Pricing of Public Offering |
| 2/27/2024 | 16:09 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free.. |
| 2/27/2024 | 16:04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/27/2024 | 15:33 | Business Wire | Oragenics Announces Proposed Public Offering |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.07 | 1.15 | 1.00 | 1.05 | 33,786 | -0.06 | -5.61% |
| 1 Month | 1.41 | 1.49 | 1.00 | 1.19 | 60,198 | -0.40 | -28.37% |
| 3 Months | 2.26 | 4.00 | 1.00 | 1.65 | 94,193 | -1.25 | -55.31% |
| 6 Months | 3.35 | 7.74 | 1.00 | 2.09 | 55,572 | -2.34 | -69.85% |
| 1 Year | 2.81 | 7.74 | 1.00 | 2.34 | 35,015 | -1.80 | -64.06% |
| 3 Years | 47.412 | 69.00 | 1.00 | 37.74 | 1,146,805 | -46.40 | -97.87% |
| 5 Years | 31.866 | 127.20 | 1.00 | 49.70 | 3,082,429 | -30.86 | -96.83% |
Oragenics Description
| Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. |
